Sen. Burr Worries Rising User Fees Helping US FDA Evade Congressional Oversight
Burr Had Raised Questions During 2017 Reauthorization Cycles
Executive Summary
Burr wants more FDA accountability in the new user fee agreements and questions whether they benefit patients. Generic approval modifications get attention at hearing.
You may also be interested in...
US FDA’s Accelerated Approval Reforms Include Dispute Resolution For Withdrawals
Allowing decisions to be reviewed by higher management levels, rather than convening administrative hearings, could save time in the withdrawal process.
FDA Seeks Input On Inactive Ingredients Database
Industry input is being sought by the FDA on its inactive ingredient database, as the US agency considers how to prioritize the addition of maximum daily exposure limits as well as mulling the removal of specific dosage form information.
Biden Requests US FDA Budget Surge: Pandemic Preparedness Money Would Increase Funding 36%
President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.